Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
30.08. | Nasdaq Stockholm AB: Change of Certified Adviser for Scandion Oncology A/S | 368 | GlobeNewswire | As from September 1, 2024, Scandion Oncology A/S, will change Certified Adviser
to Vator Securities AB.
This information is distributed at the request of the Certified Adviser, Västra
Hamnen Corporate... ► Artikel lesen | |
18.07. | Nasdaq Stockholm AB: New equity right for trading, Scandion Oncology A/S TO 3 | 184 | GlobeNewswire | At the request of Scandion Oncology, Scandion Oncology equity rights will be
traded on First North Growth Market as from July 19, 2024.
Security name: Scandion Oncology TO 3
--------------------------------------
Short... ► Artikel lesen | |
18.07. | Nasdaq Stockholm AB: New equity right for trading, Scandion Oncology A/S TO 2 | 198 | GlobeNewswire | At the request of Scandion Oncology, Scandion Oncology equity rights will be
traded on First North Growth Market as from July 19, 2024.
Security name: Scandion Oncology TO 2
--------------------------------------
Short... ► Artikel lesen | |
11.07. | Nasdaq Stockholm AB: New last trading day for paid subscription units (BTU) of Scandion Oncology | 373 | GlobeNewswire | At the request of Scandion Oncology, the last trading day in Scandion
Oncology's paid subscription units will be changed from 2024-07-11 to
2024-07-15.
Instrument: Paid subscription units... ► Artikel lesen | |
04.06. | Nasdaq Stockholm AB: Listing of subscription units and paid subscription units of Scandion Oncology | 370 | GlobeNewswire | With effect from June 05, 2024, the subscription units in Scandion Oncology
will be traded on First North Growth Market. Trading will continue up until and
including June 17, 2024.
Instrument:... ► Artikel lesen | |
31.05. | XFRA CAPITAL ADJUSTMENT INFORMATION - 31.05.2024 | 370 | Xetra Newsboard | Das Instrument 8VY DK0061031895 SCANDION ONC. DK-,0735 EQUITY wird ex Kapitalmassnahme gehandelt am 31.05.2024 The instrument 8VY DK0061031895 SCANDION ONC. DK-,0735 EQUITY is traded ex capital adjustment... ► Artikel lesen | |
SCANDION ONCOLOGY Aktie jetzt für 0€ handeln | |||||
23.05. | Scandion Oncology A/S: Scandion Oncology Announces The Final Terms Of The Rights Issue | 223 | GlobeNewswire (Europe) | On 19 April 2024, the board of directors of Scandion Oncology ("Scandion" or the "Company") resolved on the intention, subject to authorizations by the annual general meeting of the Company, to carry... ► Artikel lesen | |
22.05. | Scandion Oncology A/S: Scandion Oncology - Interim Report Q1 2024 | 126 | GlobeNewswire (Europe) | Scandion Oncology (Scandion) today announces its Interim Report Q1 2024. The following is taken from the report.
Francois Martelet, CEO:"Results from the CORIST Phase IIa trial have demonstrated impressive... ► Artikel lesen | |
13.05. | Scandion Oncology A/S: Scandion confirms positive final Phase Ib data from PANTAX trial with SCO-101 | 254 | GlobeNewswire (Europe) | Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, today announces final data from the PANTAX... ► Artikel lesen | |
28.02. | Scandion Oncology A/S: Scandion Oncology - Q4 & yearend report 2023 | 128 | GlobeNewswire (Europe) | Scandion Oncology (Scandion) today announces its Q4 & yearend report 2023. The following is taken from the report.
Francois Martelet, CEO:"Completion of and very positive topline results from part 3... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
---|